Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.
about
Elusive liver factor that causes pancreatic α cell hyperplasia: A review of literatureN-glycan remodeling on glucagon receptor is an effector of nutrient sensing by the hexosamine biosynthesis pathwayGlucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeoverActivation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling.Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonistFetal adrenal demedullation lowers circulating norepinephrine and attenuates growth restriction but not reduction of endocrine cell mass in an ovine model of intrauterine growth restrictionHypoglycemia, hyperglucagonemia, and fetoplacental defects in glucagon receptor knockout mice: a role for glucagon action in pregnancy maintenance.Angptl4 links α-cell proliferation following glucagon receptor inhibition with adipose tissue triglyceride metabolism.Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides.Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.UCP2 regulates the glucagon response to fasting and starvationcAMP-responsive element-binding protein (CREB)-regulated transcription coactivator 2 (CRTC2) promotes glucagon clearance and hepatic amino acid catabolism to regulate glucose homeostasis.Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist.The alpha-cell as target for type 2 diabetes therapy.Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX.Islet α cells and glucagon--critical regulators of energy homeostasis.Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction.Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice.Regulation of amino acid metabolism and alpha cell proliferation by glucagon.Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.Loss of mTORC1 signaling alters pancreatic α cell mass and impairs glucagon secretion.Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis.Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).Overexpression of miR-122 promotes the hepatic differentiation and maturation of mouse ESCs through a miR-122/FoxA1/HNF4a-positive feedback loop.Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.Interrupted Glucagon Signaling Reveals Hepatic α Cell Axis and Role for L-Glutamine in α Cell Proliferation.GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomyGlucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21
P2860
Q26776169-223911E7-11FE-4BEF-8606-7C69A2B2E07DQ33718411-BEA79EDF-75BC-42B3-B7AA-B822FF47E0E7Q34244209-C0C7B38F-04B7-4035-8EEB-0AB14D39D1B5Q34387308-D1D16BE6-6C98-4C79-98E3-89012820FCFFQ34490178-C9877828-2FAD-4E30-9CE3-3A84D907512CQ35003833-5C45412D-A0BD-41AA-AB2C-C66F777FB55DQ35849360-8810913B-B86D-4A47-BBBC-83B02331BFD8Q36394289-D9E35FEF-2B5F-4A47-B88D-DFA7EA95B98AQ36560559-410ADDF9-B114-4D71-9F57-AD274A8068B4Q36720548-BB080A2E-DA42-4DFD-8876-94E1AA607A0BQ36796078-B2DF1935-34CA-4610-B2DB-8687FDAC759AQ36890766-1761C6CB-4E2C-4C6C-90C1-A0825032CC75Q36913461-D37B4DA1-43EB-454A-92C2-7F7E313BC8C8Q37977335-E831C286-6E7D-4335-83C8-18D82BBDDC77Q38287579-33F6CC59-4C07-4B46-A4D3-E4B267F43420Q38409880-04DED63F-7C8F-412E-BF0D-47998187C47CQ42170069-CCE6E7EA-83B8-49F7-B695-18BB74CCF43BQ42599817-F3E5DDAE-66F1-4DBE-B43F-DD241E58AD78Q47190965-D5267953-62E0-4D33-A25F-60A2402E1974Q47625288-6EAD9180-B2D5-44A2-A671-55C055CF9DDBQ47652931-29EB9240-8FA9-4663-A19B-35894EBD924BQ47863805-866B59E1-24CF-4DC6-B569-37AADDFF71B8Q48171528-139A3360-95E9-4970-A421-F27E1979E1D9Q50852681-7ECDBF7A-F635-4977-AC5F-DDA10FF86369Q51286181-30E4966E-92DC-4E15-A406-8931E2E2D8BDQ53744774-F0D94AB1-CA7E-471D-BA94-F412BDF75A47Q57107215-C63F549A-33C4-48BE-91D2-F20354F25F84Q57109437-D1F9285F-3BDD-43CA-9CCB-59D0C44CE383
P2860
Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Polyomic profiling reveals sig ...... ucagon therapies for diabetes.
@ast
Polyomic profiling reveals sig ...... ucagon therapies for diabetes.
@en
type
label
Polyomic profiling reveals sig ...... ucagon therapies for diabetes.
@ast
Polyomic profiling reveals sig ...... ucagon therapies for diabetes.
@en
prefLabel
Polyomic profiling reveals sig ...... ucagon therapies for diabetes.
@ast
Polyomic profiling reveals sig ...... ucagon therapies for diabetes.
@en
P2093
P2860
P356
P1433
P1476
Polyomic profiling reveals sig ...... lucagon therapies for diabetes
@en
P2093
Jianxin Yang
John D Baker
Judith L Treadway
Margit L MacDougall
Michael T McDowell
Over Cabrera
William J Zavadoski
P2860
P2888
P356
10.1186/1471-2164-12-281
P407
P577
2011-06-01T00:00:00Z
P5875
P6179
1038915504